Don't miss our weekly PhD newsletter | Sign up now Don't miss our weekly PhD newsletter | Sign up now

  Defining novel biomarkers and therapeutic targets for type 2 diabetes and obesity through genetic analysis in large-scale human data sets


   Radcliffe Department of Medicine

This project is no longer listed on FindAPhD.com and may not be available.

Click here to search FindAPhD.com for PhD studentship opportunities
  Prof M I McCarthy, Prof C Lindgren  No more applications being accepted

About the Project

Background: T2D and obesity are major contributors to ill health globally. There is a critical need for novel preventative and therapeutic strategies against these diseases supported by robust stratification of individual risk and disease subtype. Progress to date has been hampered by poor understanding of the mechanisms responsible for disease development and progression. Human genetics provides a powerful means to highlight pathways of relevance to human disease, and there has been a spectacular increase in the interest in using such information to guide drug and biomarker development. This proposal seeks to build on existing and ongoing efforts at risk-variant discovery led by the supervisors and to advance understanding of disease mechanisms in ways that have direct translational relevance. It will test the hypothesis that the integration of diverse types of large-scale human genetic and genomic data, within a “mendelian randomisation” framework, represents a powerful strategy for the identification and characterisation of novel pathways causal for disease, and that such discoveries will have particular translational value in terms of providing validated biomarkers and therapeutic targets.

Description of the work: The primary focus of the research to be performed will be computational and statistical and the main activities will involve:

integration of diverse human genetics GWAS data-sets, including UKBiobank, to generate data sets of >1 million individuals, accelerating existing efforts in global T2D and obesity consortia
analysis of molecular phenotype data (proprietary and public) available to the supervisors, and gathered from tissues of particular relevance to T2D and obesity (including RNA expression data from human pancreatic islets, subcutaneous fat and skeletal muscle as well as serum proteomic and metabolomics data), the objective being to characterise the “multivariant” predictors of those phenotypes; and
application of two sample mendelian randomisation (“2SMR”) methods to link these two data types.

The objective will be to identify molecular phenotypes “causal” for disease: in other words, those that are responsible for mediating the action of genetic (and possibly non-genetic) risk factors on disease development and progression. Such biomarkers have translational potential with respect to (a) stratification of individual disease risk; (b) stratification of disease subtype; (c) monitoring need for and response to intervention; and (d) prioritisation of validated therapeutic targets for drug development. A particularly relevant example of the clinical impact of such a molecular biomarker is the use of cholesterol in relation to vascular disease.

The DPhil would be based at both the Wellcome Trust Centre for Human Genetics and the newly-established Big Data Institute. The student will receive training in diverse aspects of complex trait genetics, and will benefit particularly from the strong computational and statistical focus of the WTCHG and BDI. Through the strong network of diabetes collaborators in Oxford and beyond the student will be well-placed to further develop their understanding of related biology.

Indeed, as most of the data are already in place, it should be possible to complete the first phase of analyses in year 1 of the project, and to have identified the first wave of causal biomarkers. Depending on interest and aptitude, the fellow will have the possibility to pursue follow-up in a variety of alternative directions including: (a) extension of these methods to additional traits and reference data sets (e.g. making use of the wealth of data within UKBiobank); (b) confirmation of T2D/obesity biomarkers in prospective studies; (c) mechanistic studies in cellular and/or animal models (by collaboration with colleagues at OCDEM and MRC Harwell); and/or (d) proof-of-principle intervention studies in clinical samples (via the Oxford BRC).

This project provides an opportunity for a highly-motivated student with good computational and analytical skills, and an interest in human biology, to train in one of the internationally-leading centres at a uniquely-exciting time in the development of human genetics.

Funding Notes

All Oxford-administered funding schemes are now closed. Applicants will need to have an external source of funding in order to take up a place on course.

Please visit our website for more information on how to apply.

References

SHUNGIN D, et al. 2015. New genetic loci link adipose and insulin biology to body fat distribution. Nature, 518 (7538), pp. 187-96.
PASQUALI L, et al. 2014. Pancreatic islet enhancer clusters enriched in type 2 diabetes risk-associated variants. Nat. Genet., 46 (2), pp. 136-43.
DIABETES GENETICS REPLICATION AND META-ANALYSIS (DIAGRAM) CONSORTIUM. 2012. Large-scale association analysis provides insights into the genetic architecture and pathophysiology of type 2 diabetes. Nat. Genet., 44 (9), pp. 981-90.
MUTHER CONSORTIUM. 2011. Identification of an imprinted master trans regulator at the KLF14 locus related to multiple metabolic phenotypes. Nat. Genet., 43 (6), pp. 561-4.
HEID IM, et al. 2010. Meta-analysis identifies 13 new loci associated with waist-hip ratio and reveals sexual dimorphism in the genetic basis of fat distribution. Nat. Genet., 42 (11), pp. 949-60.

How good is research at University of Oxford in Clinical Medicine?


Research output data provided by the Research Excellence Framework (REF)

Click here to see the results for all UK universities